Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
YANCHANG PETRO
00346
CN Stock MarketDetailed Quotes
Jilin Aodong Pharmaceutical Group (000623)
- 18.21
- -0.18-0.98%
Market Closed Apr 17 15:00 CST
21.78BMarket Cap9.09P/E (TTM)
18.35High18.13Low86.44KlotVolume18.35Open18.39Prev Close157.45MTurnover0.73%Turnover Ratio9.09P/E (Static)1.20BShares22.0852wk High0.71P/B21.69BFloat Cap15.0852wk Low20.23Limit Up1.19BShs Float41.99Historical High16.55Limit Down1.20%Range %-2.93Historical Low0.50Dividend TTM18.22Avg Price48.72KlotAsk2.75%Div Yield TTM100Lot Size35.51KlotBid
Jilin Aodong Pharmaceutical Group (000623) Balance Sheet
All
YOY
| (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Current assets | ||||||||||
| Money funds | 5.02%1.16B | -4.16%1.22B | -25.22%1.52B | -34.73%1.07B | -35.65%1.11B | -31.78%1.27B | 4.59%2.03B | 46.35%1.63B | 19.59%1.72B | 23.31%1.86B |
| Transactional financial assets | 14.81%1.8B | 11.50%1.89B | 36.90%1.69B | 9.63%1.58B | -5.43%1.57B | -3.60%1.7B | -29.22%1.23B | -15.42%1.45B | 1.11%1.66B | 16.89%1.76B |
| Notes receivable and accounts receivable | -15.32%666.79M | -21.64%761.29M | -29.03%788.44M | -29.30%933.36M | -22.05%787.41M | -9.48%971.58M | 19.16%1.11B | 35.87%1.32B | 30.07%1.01B | 22.24%1.07B |
| -Notes receivable | --0 | ---- | ---- | ---- | ---- | --154.5K | -93.04%316.78K | -99.91%101.15K | ---- | ---- |
| -Accounts receivable | -15.32%666.79M | -21.63%761.29M | -29.01%788.44M | -29.29%933.36M | -22.05%787.41M | -9.49%971.43M | 19.71%1.11B | 53.51%1.32B | 46.72%1.01B | 22.24%1.07B |
| Other receivables (including interest and dividends) | 8.94%25.25M | 497.51%182.59M | -75.23%130.28M | -36.28%24.86M | -22.68%23.18M | -36.51%30.56M | -10.64%525.95M | -37.90%39.01M | -50.28%29.98M | -34.95%48.13M |
| -Dividend receivable | ---- | --154.05M | -80.55%96.11M | ---- | ---- | ---- | -6.07%494.05M | --555.84K | ---- | --9.6M |
| -Other receivable | 8.94%25.25M | ---- | 7.15%34.17M | ---- | -22.68%23.18M | ---- | -49.04%31.89M | ---- | -38.13%29.98M | ---- |
| Contractual assets | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Advance payment | -4.51%24.9M | -42.44%50.11M | -40.98%46.01M | -13.63%52.01M | -39.90%26.07M | -6.12%87.06M | -19.73%77.97M | -57.33%60.21M | -60.82%43.38M | -18.52%92.73M |
| Inventories | -14.39%802.1M | -12.73%879.19M | -8.36%891.04M | 0.42%892.79M | 7.40%936.9M | 8.06%1.01B | 6.88%972.31M | 0.76%889.09M | -0.25%872.35M | 18.22%932.33M |
| Receivable financing | -9.57%334.53M | 9.99%231.66M | 40.32%210.8M | 81.32%267.62M | -6.76%369.93M | -53.15%210.62M | -67.68%150.23M | -36.88%147.59M | 41.94%396.77M | 160.59%449.55M |
| Other current assets | -54.79%6.48M | -71.00%5.41M | -67.99%5.86M | -45.59%10M | 1.24%14.34M | 32.51%18.64M | 321.30%18.32M | -97.69%18.37M | -98.23%14.17M | -98.23%14.07M |
| Total current assets | -0.21%4.82B | -1.38%5.22B | -13.74%5.27B | -12.99%4.83B | -15.88%4.83B | -15.06%5.29B | -8.40%6.12B | -6.09%5.55B | -3.96%5.75B | 6.56%6.23B |
| Non Current assets | ||||||||||
| Other equity investment | -7.17%273.77M | -8.54%279.51M | -10.47%279.85M | -15.55%285.97M | -13.00%294.92M | -22.03%305.6M | -20.66%312.6M | -14.25%338.61M | -12.16%338.99M | -4.18%391.93M |
| Investment real estate | 15.98%25.65M | 3.22%23.17M | 2.51%23.53M | -14.49%21.78M | -14.39%22.11M | -14.28%22.45M | -5.67%22.95M | 3.26%25.47M | 3.30%25.83M | -8.59%26.19M |
| Long-term equity investment | 7.58%26.2B | 8.48%25.73B | 7.92%25.17B | 7.75%24.89B | 7.45%24.35B | 7.09%23.72B | 6.15%23.32B | 5.33%23.1B | 5.39%22.66B | 8.74%22.15B |
| Fixed assets | -3.50%2.01B | ---- | -4.01%2.03B | ---- | -2.38%2.08B | ---- | 0.07%2.11B | ---- | 1.09%2.13B | ---- |
| Constru in process | -23.59%324.63M | ---- | 5.77%439.81M | ---- | 21.55%424.87M | ---- | 130.10%415.82M | ---- | 97.08%349.54M | ---- |
| Productive biological assets | 37.95%6.97M | 39.67%7.65M | 18.70%6.67M | 18.03%7.05M | -16.28%5.05M | -16.14%5.47M | -17.34%5.62M | -17.10%5.98M | -21.19%6.04M | -21.10%6.53M |
| Intangible assets | -7.50%404.52M | 0.28%453.96M | 0.41%459.86M | 0.38%466.31M | 0.45%437.32M | 32.11%452.69M | 31.14%457.98M | 26.39%464.53M | 19.25%435.35M | -7.71%342.67M |
| Development expenditure | -67.01%34.85M | -42.18%79.65M | -39.04%81.36M | -32.53%84.26M | -32.17%105.63M | -41.28%137.77M | -41.80%133.45M | -41.90%124.88M | -20.61%155.71M | 31.43%234.63M |
| Long deferred expense | -53.19%2.78M | -52.65%3.2M | -46.88%3.84M | -29.89%5.1M | -27.92%5.95M | -50.43%6.76M | -49.86%7.22M | -51.33%7.28M | -48.79%8.25M | -15.86%13.64M |
| Deferred tax assets | -17.24%269.99M | -16.51%251.28M | -24.86%295.63M | -7.76%320.98M | 5.29%326.23M | 8.20%300.97M | 42.01%393.45M | 21.40%348M | 2.22%309.84M | -14.84%278.15M |
| Usufruct assets | -64.92%16.97M | -58.19%21.02M | -41.06%28.56M | -3.93%42.72M | 2.07%48.38M | 8.34%50.29M | -1.34%48.45M | -14.78%44.47M | 2.53%47.39M | -7.13%46.42M |
| Other non current assets | -57.11%28.4M | -23.44%62.94M | -20.50%63.58M | -15.18%67.12M | 32.58%66.22M | -48.48%82.22M | 21.92%79.97M | 42.73%79.13M | -22.95%49.94M | 42.19%159.59M |
| Total non current assets | 5.06%29.59B | 6.35%29.36B | 5.74%28.88B | 6.19%28.68B | 6.21%28.17B | 6.43%27.6B | 6.39%27.31B | 5.43%27.01B | 5.24%26.52B | 7.78%25.94B |
| Total assets | 4.29%34.42B | 5.11%34.58B | 2.18%34.15B | 2.92%33.51B | 2.28%33B | 2.26%32.9B | 3.34%33.42B | 3.27%32.56B | 3.48%32.27B | 7.54%32.17B |
| Liabilities | ||||||||||
| Current liabilities | ||||||||||
| Short term loan | -28.04%903.02M | 0.36%1.14B | 2.91%1.15B | -19.40%1.35B | 85.01%1.25B | 46.23%1.14B | 39.27%1.12B | 138.07%1.67B | 4.15%678.31M | 33.89%778.17M |
| Notes payable and accounts payable | -27.08%310.42M | -15.54%360.65M | -14.10%380.88M | 34.78%401.37M | 1.70%425.71M | 3.87%427.01M | 6.34%443.4M | -27.78%297.79M | -7.18%418.59M | 18.22%411.1M |
| -Notes payable | 76.11%14.65M | 118.23%8.5M | -75.20%2.39M | 360.19%14M | 41.89%8.32M | -69.87%3.89M | -8.58%9.65M | -74.13%3.04M | -58.59%5.86M | -9.43%12.92M |
| -Accounts payable | -29.14%295.76M | -16.77%352.15M | -12.74%378.48M | 31.43%387.37M | 1.13%417.39M | 6.27%423.12M | 6.72%433.75M | -26.42%294.75M | -5.51%412.72M | 19.40%398.17M |
| Contract liabilities | -12.08%30.5M | -25.26%29.09M | -7.27%26.8M | -15.53%25.27M | 32.12%34.69M | 102.08%38.93M | 37.61%28.9M | 43.07%29.92M | -68.08%26.26M | 9.95%19.26M |
| Advance receipts | -24.64%1.17M | 45.56%2.72M | -4.73%1.05M | 1.87%977.58K | 54.12%1.56M | 7.03%1.87M | -7.07%1.1M | -96.72%959.68K | -96.52%1.01M | -94.02%1.75M |
| Salaries payable | 53.05%100.78M | -1.83%31.05M | 22.93%39.39M | -2.27%63.58M | -11.60%65.84M | -4.56%31.62M | -22.64%32.04M | -14.92%65.06M | -31.43%74.49M | -4.99%33.14M |
| Taxs payable | -26.69%17.1M | 16.58%26.17M | 27.71%18.92M | -2.54%39.55M | -65.22%23.33M | -59.30%22.45M | -57.59%14.82M | -7.47%40.58M | 20.81%67.08M | 2.27%55.16M |
| Other payable (including interest and dividends) | -2.69%613.94M | 23.58%829M | -33.22%972.18M | -28.15%680.68M | -27.16%630.91M | -19.82%670.85M | 26.94%1.46B | 29.97%947.38M | 7.09%866.16M | 26.11%836.68M |
| -Interest payable | ---- | 0.00%15.25M | -6.62%6.42M | 6,425.23%32.7M | -35.73%24.07M | -42.58%15.25M | -52.43%6.88M | -79.94%501.11K | 20.74%37.45M | 24.55%26.55M |
| -Dividend payable | -99.22%5.19K | 35,123.49%234.48M | -50.89%352.38M | 12,735.28%665.7K | 12,735.28%665.7K | 12,735.28%665.7K | 112.23%717.54M | 0.00%5.19K | 0.00%5.19K | 0.00%5.19K |
| -Other payable | 1.28%613.93M | -11.55%579.27M | -16.13%613.38M | -31.64%647.32M | -26.85%606.18M | -19.16%654.94M | -7.92%731.37M | 30.35%946.87M | 6.55%828.71M | 26.16%810.12M |
| Non current liabilities due within one year | 48.42%33.36M | -43.64%12.63M | -22.78%16.18M | 19.48%21.8M | -99.04%22.48M | -99.06%22.42M | -99.11%20.96M | -99.22%18.24M | 12,691.29%2.33B | 13,206.92%2.38B |
| Other current liabilities | -14.86%3.77M | -23.02%3.72M | -99.16%3.39M | -99.19%3.26M | 35.12%4.42M | 101.56%4.83M | 15,355.26%403.62M | 15,128.22%403.72M | -69.32%3.27M | 5.49%2.39M |
| Total current liabilities | -18.26%2.01B | 3.35%2.44B | -25.83%2.61B | -25.65%2.58B | -44.85%2.46B | -47.85%2.36B | -27.20%3.52B | -20.40%3.47B | 101.67%4.47B | 158.63%4.52B |
| Current liabilities | ||||||||||
| Long term loan | --302.1M | --90M | --90M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Bonds payable | 0.20%997.24M | 0.20%996.73M | 0.20%996.21M | --995.71M | --995.22M | --994.72M | --994.23M | ---- | ---- | ---- |
| Deferred tax liabilities | -93.26%1.36M | -53.98%14.1M | -48.82%15.04M | -35.05%18.92M | -32.84%20.17M | 138.92%30.64M | 80.43%29.38M | 65.50%29.13M | 15.26%30.03M | 104.64%12.82M |
| Long term deferred income | -4.86%212.98M | -6.19%215.26M | -6.32%220.01M | -8.92%219.22M | -9.50%223.87M | -16.04%229.48M | -11.93%234.84M | -13.06%240.7M | -12.15%247.38M | -5.81%273.33M |
| Lease liabilities | -80.73%3.18M | -76.04%5.5M | -63.52%7.96M | -20.65%15.2M | -23.19%16.51M | 2.85%22.97M | 5.68%21.82M | -8.83%19.15M | 22.45%21.49M | 9.03%22.34M |
| Total non current liabilities | 20.79%1.52B | 3.43%1.32B | 3.82%1.33B | 332.22%1.25B | 320.13%1.26B | 314.22%1.28B | 321.72%1.28B | -8.40%288.99M | -88.63%298.9M | -88.13%308.49M |
| Total liabilities | -5.07%3.53B | 3.38%3.76B | -17.92%3.94B | 1.84%3.83B | -21.96%3.72B | -24.72%3.64B | -6.58%4.8B | -19.60%3.76B | -1.60%4.77B | 11.12%4.83B |
| Shareholders equity | ||||||||||
| Paid-in capital | 0.00%1.2B | 0.00%1.2B | 0.00%1.2B | -3.64%1.2B | 2.35%1.2B | 2.81%1.2B | 2.82%1.2B | 6.70%1.24B | 0.46%1.17B | 0.01%1.16B |
| Other equity instruments | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -3.14%542.29M | -0.07%559.65M |
| Capital reserve funds | 0.97%4.9B | 0.96%4.9B | 1.03%4.9B | -11.38%4.9B | 20.24%4.85B | 22.82%4.85B | 22.90%4.85B | 40.12%5.53B | 2.24%4.03B | 0.13%3.95B |
| Surplus reserve funds | 9.31%2.93B | 7.84%2.68B | 7.84%2.68B | 7.84%2.68B | 7.84%2.68B | 5.79%2.49B | 5.80%2.49B | 5.80%2.49B | 5.80%2.49B | 8.03%2.35B |
| Retained profit | 7.88%21.34B | 7.77%21.46B | 7.86%20.71B | 3.96%20.3B | 2.06%19.78B | 3.01%19.91B | 0.45%19.2B | 3.44%19.53B | 5.41%19.38B | 9.41%19.33B |
| Less:Treasury stock | 40.00%420.01M | --420.01M | --420.01M | -41.67%420.01M | -58.34%300M | ---- | ---- | 26.31%720.07M | 26.31%720.07M | 12.72%620.05M |
| Other composite income | -11.88%717.38M | 36.29%754.5M | 43.81%887.33M | 68.19%766.93M | 158.69%814.1M | 80.89%553.58M | 79.98%617M | 113.93%455.99M | 62.35%314.7M | -4.15%306.04M |
| Shareholders equity without minority interests | 5.65%30.67B | 5.41%30.57B | 5.66%29.96B | 3.17%29.43B | 6.67%29.03B | 7.25%29B | 5.37%28.36B | 7.46%28.52B | 4.52%27.21B | 6.96%27.04B |
| Minority interests | -13.52%220.23M | -4.87%249.03M | -6.35%251.61M | -8.19%254.32M | -11.58%254.65M | -12.54%261.78M | -8.69%268.67M | -10.13%277M | -5.12%288.01M | 4.31%299.3M |
| Total shareholder equity | 5.48%30.89B | 5.32%30.82B | 5.55%30.21B | 3.06%29.68B | 6.48%29.28B | 7.03%29.26B | 5.21%28.62B | 7.26%28.8B | 4.41%27.5B | 6.93%27.34B |
| Total liabilityies and equity | 4.29%34.42B | 5.11%34.58B | 2.18%34.15B | 2.92%33.51B | 2.28%33B | 2.26%32.9B | 3.34%33.42B | 3.27%32.56B | 3.48%32.27B | 7.54%32.17B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Beijing Dehao International Certified Public Accountants (Special General Partnership) | -- | -- | -- | Beijing Dehao International Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhongzhun Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
Lebanon and Israel will implement a 10-day ceasefire! Iran's foreign minister, based on the Lebanon ceasefire agreement, announced the compl
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm